<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01811355</url>
  </required_header>
  <id_info>
    <org_study_id>378164</org_study_id>
    <nct_id>NCT01811355</nct_id>
  </id_info>
  <brief_title>Mexiletine for the Treatment of Muscle Cramps in ALS</brief_title>
  <official_title>Mexiletine for the Treatment of Muscle Cramps in ALS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bjorn Oskarsson, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ALS Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if mexiletine is effective for the treatment of
      muscle cramps in Amyotrophic Lateral Sclerosis (ALS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:

      Many ALS patients suffer from painful muscle cramps, but unfortunately we do not have any
      medication proven to help muscle cramps in ALS. Reducing the pain caused by cramps - which
      can be debilitating - could help people living with ALS.

      Muscle cramps are sudden, painful, and involuntary contractions of a muscle. They are caused
      by nerve dysfunction. When we examine nerves and muscles electrically, we see cramps as
      bursts of high-frequency (up to150 Hz) firing of the motor nerve cells. Cramps in ALS are
      believed to be the result of an increase of persistent sodium currents in the sick lower
      motor nerve cells.

      A medication called Quinine was for many years the commonly used drug for controlling cramps
      in ALS, but the FDA has advised against its use for cramps because of its potential risks
      (e.g., death). Today there is no agreement on how to treat cramps in the ALS. The American
      Academy of Neurology recently encouraged further studies of the treatment of muscle cramps
      and suggested lidocaine as one of a few drugs of special interest.

      Mexiletine:

      Mexiletine is a medication closely related to lidocaine that can be taken by mouth (instead
      of being injected). Mexiletine stops the type of sodium currents that are thought to cause
      muscle cramps. Mexiletine is a relatively older medication that has been extensively studied
      in humans. It has been shown to reduce the electrical measures of muscle cramps for other
      disease conditions. For example, in patients with another severe nerve disease -
      Machado-Joseph disease (SCA3) - mexiletine treatment led to a decrease in the average number
      of muscle cramps from 24 to 3 cramps per month.. The safety profile of mexiletine is good,
      with the most frequent side effects being nausea or other abdominal symptoms. These side
      effects are rare at the doses (300 mg/day) used in this study. In patients with normal heart
      function, mexiletine has a minimal effect on heart rhythm. In previous clinical trials, no
      subject developed any serious heart rate problem.

      Experimental Plan:

      Using multiple sites within the State of California we will quickly enroll a small number
      (N=30) of ALS patients with severe muscle cramps. The study is a double-blinded, placebo
      controlled (i.e., the investigator and the participant does not know if the pills contain
      mexiletine or placebo), crossover (all subjects receive two weeks of mexiletine and two weeks
      of placebo) study.

      After a one week run in, participants will be evaluated on their ability to fill out the
      cramp diary. Participants who filled out their diary will be randomly assigned to either
      mexiletine or placebo for their first two weeks. For the first three days of each 2-week
      period, one 150mg capsule will be taken at bed time. For day 4 to 14 one capsule twice per
      day will be taken. Each treatment period will be 2 weeks with an intervening 1 week washout
      period - for a total study length of 6 weeks. Safety will be monitored with liver function
      studies and EKG's.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Daily Muscle Cramps</measure>
    <time_frame>6 weeks</time_frame>
    <description>The average of the daily recording of number of muscle cramps that occurred in the last 24 hours- over a 6 week period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cramp Severity</measure>
    <time_frame>6 weeks</time_frame>
    <description>Daily cramp severity was rated on the 100-unit visual analog scale. Scores ranged from 0 to 100, with 100 being the greatest amount of cramp severity</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Muscle Cramps in Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Mexiletine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mexiletine, capsule, 150mg, PO BID, 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, capsule, PO BID, 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mexiletine</intervention_name>
    <description>Sodium channel blocker</description>
    <arm_group_label>Mexiletine</arm_group_label>
    <other_name>Mexetil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ALS diagnosed according to El Escorial criteria (Awaji version) as: Possible,
             Probable, or Definite.

          -  Experiencing cramps as a moderate or severe symptom as defined by willingness to take
             a medication for the symptom

          -  ≥2 cramps per week during run in week

          -  Life expectancy &gt; 6 months, estimated by clinician

          -  Able to take drug capsule by mouth

          -  No significant EKG abnormality on screening

          -  aspartate aminotransferase / alanine aminotransferase &lt;2x upper limit of normal
             measured at screening

          -  Having successfully filled out the cramp diary and cramp and fasciculation scales on
             six out of the last seven days of run in period

        Exclusion Criteria:

          -  Inability to communicate by telephone or email

          -  Allergy/ known sensitivity to mexiletine

          -  Prior use of mexiletine

          -  AV block unless subject has pacemaker

          -  Cardiac arrhythmia

          -  Prior myocardial infarction

          -  Other significant EKG abnormality

          -  Liver disease

          -  History of leucopenia (WBC &lt;3,500/mm3)

          -  Epilepsy

          -  Other serious and unstable medical condition

          -  Pregnant woman

          -  Breastfeeding woman

          -  Active drug or alcohol use or dependence that, in the opinion of the site
             investigator, would interfere with adherence to study requirements

          -  Use of quinidine (alone or as a component of Nuedexta®) during the study

          -  Inability or unwillingness of subject to give written informed consent

          -  Woman of childbearing potential, not willing to use at least two approved methods of
             contraception

          -  Use of a prohibited medication during study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bjorn Oskarsson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UC Davis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCD Telehealth Network - Lake Almanor Clinic</name>
      <address>
        <city>Chester</city>
        <state>California</state>
        <zip>96020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD Department of Neurosciences ALS Clinical Trials (ACT) Program</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Neuromuscular Research Program</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCD Telehealth Network</name>
      <address>
        <city>Multiple Locations</city>
        <state>California</state>
        <zip>Various</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Irvine Health ALS &amp; Neuromuscular Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC, Davis Medical Center ALS Clinic</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2013</study_first_submitted>
  <study_first_submitted_qc>March 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2013</study_first_posted>
  <results_first_submitted>April 3, 2017</results_first_submitted>
  <results_first_submitted_qc>May 23, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 27, 2017</results_first_posted>
  <last_update_submitted>July 28, 2017</last_update_submitted>
  <last_update_submitted_qc>July 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Davis</investigator_affiliation>
    <investigator_full_name>Bjorn Oskarsson, MD</investigator_full_name>
    <investigator_title>Assistant Professor of Clinical Neurology</investigator_title>
  </responsible_party>
  <keyword>Muscle cramps</keyword>
  <keyword>Cramp</keyword>
  <keyword>ALS</keyword>
  <keyword>Amyotrophic Lateral Sclerosis</keyword>
  <keyword>Lou Gehrig's disease</keyword>
  <keyword>Motor Neuron Disease</keyword>
  <keyword>MND</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Muscle Cramp</mesh_term>
    <mesh_term>Spasm</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mexiletine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Of 28 patients who signed consent, 5 did not meet inclusion criteria because of past myocardial infarction (n=1), long QT syndrome (n=1), AV block (n=1), no muscle cramps (n=1), and hospitalization during the screening period that resulted in inability to complete a screening diary and follow-up (n=1) .</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Mexiletine First/Placebo Second</title>
          <description>Mexiletine, capsule, 150mg, PO BID, 14 days
Placebo, capsule, PO BID, 14 days</description>
        </group>
        <group group_id="P2">
          <title>Placebo First/Mexiletine Second</title>
          <description>Placebo, capsule, PO BID, 14 days
Mexiletine, capsule, 150mg, PO BID, 14 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Dose</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Dose</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Total Subjects Enrolled</title>
          <description>A total of 23 subjects were enrolled. 11 were randomized to receive study drug first, followed by placebo. 12 subjects received placebo first and study drug second. Overall participant characteristics are displayed in the baseline table.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.4" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>males</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>females</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Daily Muscle Cramps</title>
        <description>The average of the daily recording of number of muscle cramps that occurred in the last 24 hours- over a 6 week period.</description>
        <time_frame>6 weeks</time_frame>
        <population>Among the 21 patients who completed the study, 1 patient did not return the outcome diary, which resulted in 20 patients available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Mexiletine First/Placebo Second</title>
            <description>Mexiletine, capsule, 150mg, PO BID, 14 days
Placebo, capsule, PO BID, 14 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo First/Mexiletine Second</title>
            <description>Placebo, capsule, PO BID, 14 days
Mexiletine, capsule, 150mg, PO BID, 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Daily Muscle Cramps</title>
          <description>The average of the daily recording of number of muscle cramps that occurred in the last 24 hours- over a 6 week period.</description>
          <population>Among the 21 patients who completed the study, 1 patient did not return the outcome diary, which resulted in 20 patients available for analysis.</population>
          <units>Cramps per 24 hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Placebo Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" spread="8.1"/>
                    <measurement group_id="O2" value="4.7" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexiletine Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="8.0"/>
                    <measurement group_id="O2" value="2.5" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difference Between</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="2.9"/>
                    <measurement group_id="O2" value="2.2" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cramp Severity</title>
        <description>Daily cramp severity was rated on the 100-unit visual analog scale. Scores ranged from 0 to 100, with 100 being the greatest amount of cramp severity</description>
        <time_frame>6 weeks</time_frame>
        <population>Among the 21 patients who completed the study, 1 patient did not return the outcome diary, which resulted in 20 patients available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Mexiletine First</title>
            <description>Mexiletine, capsule, 150mg, PO BID, 14 days
Mexiletine: Sodium channel blocker</description>
          </group>
          <group group_id="O2">
            <title>Placebo First</title>
            <description>Placebo, capsule, PO BID, 14 days
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Cramp Severity</title>
          <description>Daily cramp severity was rated on the 100-unit visual analog scale. Scores ranged from 0 to 100, with 100 being the greatest amount of cramp severity</description>
          <population>Among the 21 patients who completed the study, 1 patient did not return the outcome diary, which resulted in 20 patients available for analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Placebo Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.6" spread="31.0"/>
                    <measurement group_id="O2" value="44.7" spread="26.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexiletine Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.1" spread="16.8"/>
                    <measurement group_id="O2" value="32.8" spread="27.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difference Between</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.5" spread="40.6"/>
                    <measurement group_id="O2" value="12.0" spread="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Mexiletine</title>
          <description>Mexiletine, capsule, 150mg, PO BID, 14 days
Mexiletine: Sodium channel blocker</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo, capsule, PO BID, 14 days
Placebo: Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Congestion</sub_title>
                <description>Mild</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <description>Mild</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Mild</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Mild</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizzines</sub_title>
                <description>Mild</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>Mild</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Increased urination</sub_title>
                <description>Mild</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chest tightness</sub_title>
                <description>Mild</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Itchiness</sub_title>
                <description>Mild</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Bjorn Oskarsson</name_or_title>
      <organization>Mayo Clinic, Jacksonville</organization>
      <phone>9049536896</phone>
      <email>oskarsson.bjorn@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

